Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 214 | 47 | 163 |
| Samples | 206 | 45 | 158 |
| Peptides | 154 | 26 | 131 |
Function
PRKAR2B · Protein kinase cAMP-dependent type II regulatory subunit beta
cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. The protein encoded by this gene is one of the regulatory subunits. This subunit can be phosphorylated by the activated catalytic subunit. This subunit has been shown to interact with and suppress the transcriptional activity of the cAMP responsive element binding protein 1 (CREB1) in activated T cells. Knockout studies in mice suggest that this subunit may play an important role in regulating energy balance and adiposity. The studies also suggest that this subunit may mediate the gene induction and cataleptic behavior induced by haloperidol. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000265717 | P31323 | 214 | 154 |
Gene Properties
Recurrent Mutations
All 154 amino-acid changes on canonical ENST00000265717 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PRKAR2B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PRKAR2B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Melanoma | 2/210 1% | 24/1899 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 13/304 4% | 4/1390 0% |
| Other Solid Cancers | 0/94 0% | 15/1515 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 6/810 1% |
| Endometrial Carcinoma | 1/42 2% | 5/612 1% |
| Gastric Carcinoma | 1/74 1% | 16/1809 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Colorectal Carcinoma | 6/143 4% | 19/3239 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 12/1592 1% |
| Bladder Carcinoma | 0/58 0% | 6/956 1% |
| Head and Neck Carcinoma | 1/85 1% | 8/1574 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Biliary Tract Carcinoma | 2/54 4% | 3/950 0% |
| Hepatocellular Carcinoma | 0/46 0% | 11/2210 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Ovarian Carcinoma | 2/109 2% | 1/998 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 4/2550 0% |
| Breast Carcinoma | 0/144 0% | 5/3264 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
| Other Sarcomas | 1/69 1% | 0/699 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
Mutation Distribution
Where PRKAR2B is mutated · all tissues, split by cell line vs tissue
How many mutations in PRKAR2B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 214 mutations in PRKAR2B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|